The Power of Metastatic Breast Cancer Retreats With Lillie Shockney and Janie Metsker
Keira Smith
Expert Analysis
Oncology Data Advisor™ · The Power of Metastatic Breast Cancer Retreats With Lillie Shockney and Janie Metsker In 2006, Lillie Shockney, Professor of Surgery at Johns Hopkins University, launched a retreat program for patients with metastatic breast cancer, a weekend-long retreat in which patients, their spouses, and caregivers can foc...
An Introduction to Breast Cancer Therapies: A Patient Resource From Samuel Kareff, MD, MPH
Keira Smith
Expert Analysis
Oncology Data Advisor™ · An Introduction to Breast Cancer Therapies: A Patient Resource From Samuel Kareff, MD, MPH In this interview with Oncology Data Advisor, Dr. Samuel Kareff, a Hematology-Oncology Fellow at Sylvester Comprehensive Cancer Center of the University of Miami, provides a comprehensive overview of the current and emerging therapies used in the treatment of breast cancer, serving as a valuable resource to share with patients who may be discussing these options with their oncology team.  
The Power of Metastatic Breast Cancer Retreats With Lillie Shockney and Janie Metsker: Part 2
Keira Smith
Expert Analysis
In 2006, Lillie Shockney, Professor of Surgery at Johns Hopkins University, launched a retreat program for patients with metastatic breast cancer, a weekend-long retreat in which patients, their spouses, and caregivers can focus on communication, support, relationships, personal reflection, and laughter. In 2016, Janie Metsker, Clinical Coordinator at the Koontz Center for Advanced Breast Cancer at St. Luke's Hospital, launched these retreats at her own institution. In this interview with Oncology Data Advisor, Ms. Shockney and Ms. Metsker reflect on the impactful moments that take place during the retreats and their profound significance for the patients who attend.  Watch the first part of Ms. Shockney and Ms. Metsker's conversation here!
The Power of Metastatic Breast Cancer Retreats With Lillie Shockney and Janie Metsker: Part 1
Keira Smith
Expert Analysis
In 2006, Lillie Shockney, Professor of Surgery at Johns Hopkins University, launched a retreat program for patients with metastatic breast cancer, a weekend-long retreat in which patients, their spouses, and caregivers can focus on communication, support, relationships, personal reflection, and laughter. In 2016, Janie Metsker, Clinical Coordinator at the Koontz Center for Advanced Breast Cancer at St. Luke's Hospital, launched these retreats at her own institution. In this interview with Oncology Data Advisor, Ms. Shockney and Ms. Metsker reflect on the impactful moments that take place during the retreats and their profound significance for the patients who attend.  
Men Can Get Breast Cancer Too: Valerie Brutus, MD, FACS
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Men Can Get Breast Cancer Too: Valerie Brutus, MD, FACS In honor of Breast Cancer Awareness Month, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford HealthCare, spoke with Oncology Data Advisor to raise awareness about the reality that men can get breast cancer too. Dr. Brutus explains the risk factors and the conversations that men can have with their health care providers to understand their individual risks for breast cancer. 
Bringing Attention to Breast Cancer Reconstructive Surgery Options With Elizabeth Stirling Craig, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Bringing Attention to Breast Cancer Reconstructive Surgery Options With Elizabeth Stirling Craig, MD In this latest Breast Cancer Awareness Month interview, Dr. Elizabeth Stirling Craig, Director of Microvascular Breast Reconstruction at St. Vincent's Medical Center of Hartford HealthCare, explains the microsurgical techniques that she performs as a breast reconstructive surgeon and shares the importance of providing patients with a clear picture of the reconstructive options that are available to them. 
A Faculty Preview of ODACon™ 2022 Supportive Care Summit: Managing Toxicities of Novel Breast Cancer Therapies
Keira Smith
Expert Analysis
Recently, Oncology Data Advisor hosted a live faculty panel discussion in advance of ODACon™ 2022 Supportive Care Summit: Managing Toxicities of Novel Breast Cancer Therapies, featuring the conference's four expert nurse speakers: Dr. Constance Visovsky, Abbey Kaler, Julia LaBarbera, and Janie Metsker. In their conversation, they gave a preview of ...
An Introduction to Breast Cancer Therapies: A Patient Resource From Samuel Kareff, MD, MPH
Keira Smith
Expert Analysis
In this interview with Oncology Data Advisor, Dr. Samuel Kareff, a Hematology-Oncology Fellow at Sylvester Comprehensive Cancer Center of the University of Miami, provides a comprehensive overview of the current and emerging therapies used in the treatment of breast cancer, serving as a valuable resource to share with patients who may be discussing these options with their oncology team.  
Breast Cancer Is Not Just One Disease: Exploring Lobular Breast Cancer Research With Jason Mouabbi, MD
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Breast Cancer Is Not Just One Disease: Lobular Breast Cancer Research With Jason Mouabbi, MD Understanding the various subtypes of breast cancer is critical, as treatment selection and potential outcomes depend heavily on subtype. In this latest Oncology Data Advisor interview for Breast Cancer Awareness Month, Dr. Jason Mouabbi, an Assistant Professor at the University of Texas MD Anderson Cancer Center, sheds light on lobular breast, an often-understudied subtype. Dr. Mouabbi shares his passion for raising awareness about lobular breast cancer and his goal of better understanding it at the genomic level to develop novel therapeutic options.   
Raising Awareness for Breast Cancer Risks in Transgender Patients With Valerie Brutus, MD, FACS
Keira Smith
Expert Analysis
In honor of Breast Cancer Awareness Month, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford HealthCare, spoke with Oncology Data Advisor about the risks for breast cancer in transgender individuals. Dr. Brutus shares the importance of starting the conversation about individualized risk assessment to provide the most appropriate screening recommendations and personalized care for every patient.  
Men Can Get Breast Cancer Too: Valerie Brutus, MD, FACS
Keira Smith
Expert Analysis
In honor of Breast Cancer Awareness Month, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center of Hartford HealthCare, spoke with Oncology Data Advisor to raise awareness about the reality that men can get breast cancer too. Dr. Brutus explains the risk factors and the conversations that men can have with their health care providers to understand their individual risks for breast cancer. 
Guiding Breast Cancer Surgical Decisions With Valerie Brutus, MD, FACS
Keira Smith
Expert Analysis
Oncology Data Advisor™ · Guiding Breast Cancer Surgical Decisions With Valerie Brutus, MD, FACS In this interview with Oncology Data Advisor, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center, discusses the significance of Magtrace™, a liquid tracer which has recently become a game changer in guiding surgical decisions for patients with breast cancer.  
Significant Knowledge Gains Acquired for Treating Metastatic Breast Cancer
Lyn Brook
Practice Patterns
An educational enduring online activity provided by i3 Health has provided knowledge gains pertaining to enhancing treatment tolerability, adherence, and patient-centered care for metastatic breast cancer. In the United States, breast cancer accounts for approximately 30% of cancer diagnoses among women and is the second-leading cause of cancer dea...
Guiding Breast Cancer Surgical Decisions With Valerie Brutus, MD, FACS
Keira Smith
Expert Analysis
In this interview with Oncology Data Advisor, Dr. Valerie Brutus, a Breast Surgical Oncologist at St. Vincent's Medical Center, discusses the significance of Magtrace™, a liquid tracer which has recently become a game changer in guiding surgical decisions for patients with breast cancer.  
Trastuzumab Deruxtecan Approved for Treatment of HER2-Low Breast Cancer
Lyn Brook
FDA Updates
The FDA has approved fam-trastuzumab deruxtecan-nxki (Enhertu®, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)–low breast cancer. This treatment is indicated for patients who have previously undergone chemotherapy in the metastatic setting or who developed disease recurrence ...
Understanding Antibody-Drug Conjugates and Their Use in the Treatment of Breast Cancer With Ian Krop, MD, PhD
Elizabeth Heller, PhD
Expert Analysis
Oncology Data Advisor™ · Patritumab Deruxtecan for HER3-Expressing Metastatic Breast Cancer: Ian Krop, MD, PhD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Ian Krop, Director of the Yale Cancer Center Clinical Trials Office, sat down with Oncology Data Advisor to discuss his research and the data he presented regarding the HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) for treatment of metastatic breast cancer.This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMED.  
Bridging Disparities in Breast Cancer Morbidity and Mortality in Women of Color With Jessica Jones, MD
Eden Maack
Expert Analysis
Oncology Data Advisor™ · Breast Cancer Prevention and Disparities: Jessica Jones, MD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Jessica Jones, Assistant Professor of Oncology at the University of Texas (UT) Health System, sat down with Oncology Data Advisor to discuss her work in cancer detection and cancer prevention in Black women with a higher risk of developing breast cancer and bridging the racial gap in breast cancer morbidity and mortality with early detection and prevention.This podcast episode was recorded live at the 2022 ASCO Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed.
Fam-Trastuzumab Deruxtecan-nxki Approved for Treatment of Breast Cancer
Lyn Brook
FDA Updates
The FDA has approved fam-trastuzumab deruxtecan-nxki (Enhertu®, Daiichi Sankyo, Inc.) for treatment of patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)–positive breast cancer. The approval is specific to individuals who have had prior treatment with an anti–HER2-based regimen in the metastatic, neoadjuvant, o...
Applying Recent Advances to Personalized Breast Cancer Care, A Breast Surgical Oncologist’s View: Brigid Killelea, MD, FACS
Keira Smith
Expert Analysis
Over recent years, numerous developments have occurred in the fields of breast cancer prevention, genetic testing, screening, and surgical procedures. In this interview, Dr. Brigid Killelea, Medical Director of Breast Surgery at Hartford HealthCare, explains strategies for incorporating these advances into the care of patients with breast cancer.  
Making Strides in Breast Cancer Treatment With Richard Zelkowitz, MD
Keira Smith
Expert Analysis
Significant progress has been made in numerous facets of breast cancer care in recent years, including developments in treatment, imaging, pathology, radiation, and surgery. In this interview, Dr. Richard Zelkowitz, a Regional Medical Director of the Breast Program at Hartford HealthCare, highlights the advances that have been made and explains the importance of subspecialties in ensuring that patients with breast cancer receive the most individualized care possible.  

Copyright © 2022 Oncology Data Advisor. All rights reserved.